The Peptide Interim Access Policy: What It Would and Would Not Do

What was submitted

The Office of Information and Regulatory Affairs, part of the White House Office of Management and Budget, reviews significant regulatory actions before agencies publish them. Its public record shows that on October 14, 2026 it received a submission from HHS titled "Interim Access Policy for Compounding Using Certain Peptides". The entry is classified as a notice, carries no legal deadline, and was pending review as of mid-October.^[1]

Reuters, the Associated Press, and STAT reported the submission on October 15.^[3] None had seen the text. Arrival at the review office is a procedural step: it does not guarantee that a policy will be published, or that it will be published unchanged.

What it is expected to do

The reporting describes a policy under which FDA would choose not to enforce certain requirements against 503A compounding pharmacies that prepare specific peptides, while formal decisions are pending. That is enforcement discretion. It is a familiar tool: FDA already operates interim enforcement policies for bulk substances that have been nominated for the 503A list but not yet evaluated, and one law firm has suggested the new policy could serve a similar bridging function.^[1]

The same firm stresses that the title alone does not establish how FDA intends to use it. Until the text is published, the conditions are unknown. Those might cover prescription requirements, ingredient sourcing, sterile preparation, and which forms of each substance qualify.

Which peptides it may cover

This is the question everyone is asking, and the public record does not answer it. The only named substance so far is BPC-157, which AP reported based on two unnamed sources.^[4]

The obvious candidates are the seven reviewed at the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting. The committee recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A bulks list and voted against DSIP. Those recommendations are not binding, and the policy's timing does not establish that it covers any of them. Pharmacies, prescribers, and patients should not assume coverage until the text says so.

What it would not change

Several things are clear even without the text, because they follow from the type of document it is.

• It is not an approval. Compounded drugs are not FDA-approved, and an enforcement policy does not change that. No peptide would gain the safety and efficacy review that approval requires.
• It does not change the bulks list. Adding a substance to the 503A bulks list requires notice-and-comment rulemaking, and the July votes did not amend the list. As of mid-October, no peptide had been added.^[2]
• It does not cover outsourcing facilities. 503B facilities operate under a separate framework with a separate bulks list.
• It does not resolve state law. State pharmacy boards set their own rules, and a federal enforcement policy does not override them.
• It does nothing for research-use-only sellers. The policy concerns licensed pharmacies dispensing against prescriptions. Selling peptides labelled for research but marketed for human use is a separate matter, and the legal pressure on it is rising, as our coverage of Lilly's retatrutide lawsuits and research-peptide legality explains.
• It does not change anti-doping rules. USADA says the 2027 World Anti-Doping Agency Prohibited List, in force from January 1, 2027, names peptides in general within its category for non-approved substances. BPC-157 was already prohibited there.^[8]

The quality question it does not answer

FDA's own reviewers recommended against all seven July peptides. They cited incomplete characterisation, little or no human efficacy data for the proposed routes, incomplete safety data, and unassessed immunogenicity. An enforcement policy would not resolve any of those points. It would move the practical question from whether a peptide can be compounded to whether the ingredient a pharmacy uses is what it claims to be.

That question is not hypothetical. In 2026 the CDC investigated illness linked to compounded injectable glutathione, a tripeptide, prepared from dietary-supplement-grade ingredient. More than 25 people fell ill across Texas, Washington, Florida, and New York, and at least three were hospitalised. FDA reminded compounders on August 27 not to use supplement-grade glutathione for injectable products.^[6][7] Glutathione can be compounded. The problem was the quality of what went into it. Our evidence calibration for the PCAC peptides covers what the research does and does not support for each compound.

What to watch

• The published text. Which peptides are named, which forms qualify, and what conditions apply to prescribing, sourcing, and sterile preparation.
• Whether rulemaking continues. An interim policy could sit alongside formal rulemaking on the bulks list or substitute for it in practice.
• The February 2027 committee review. FDA has said the committee will consider GHK-Cu, LL-37, Melanotan II, dihexa acetate, and PEG-MGF before the end of February 2027. Our preview of that meeting covers each one.
• State responses. Pharmacy boards may respond differently, and state rules can be stricter than federal ones.

Where this leaves patients and prescribers

Nothing changed legally on October 14. A policy under review is not in force, and its contents are unknown. If it is published in the form reporting describes, it would most likely make it easier for licensed pharmacies to compound some peptides against a prescription, while leaving their regulatory status as unapproved drugs untouched. That would not make the evidence for any of these compounds stronger, and it would not make research-use-only products lawful. The route with real oversight remains a licensed clinician working with a licensed pharmacy, and the useful questions to ask are about ingredient sourcing and quality rather than whether a peptide is "allowed".